Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 13;7(1):15.
doi: 10.1038/s41392-022-00875-6.

A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors

Svenja Mergener  1   2 , Samuel Peña-Llopis  3   4
Affiliations
Comment

A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors

Svenja Mergener et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The inactivation of tumor suppressor genes (TSGs) fosters immune evasion to promote tumorigenesis. BALB/c tumor cells from the breast (4T1) and colon (CT26) were screened with a druggable CRISPR library targeting ~7500 genes. As expected, cells with loss of essential genes (depicted in green) were dropped out from the screen after ten population doublings in vitro or in vivo. However, cells knocking out TSGs (depicted in red) were largely enriched in tumors from cells implanted subcutaneously on flanks of wild-type (WT) immunocompetent mice compared to SCID immunodeficient mice or cells grown in vitro. These results highlight a new role of the loss of TSGs in evading immune surveillance to support tumor survival and growth.
See this image and copyright information in PMC

Comment on

References

    1. Martin TD, et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science. 2021;373:1327–1335. doi: 10.1126/science.abg5784. - DOI - PubMed
    1. Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002;3:991–998. doi: 10.1038/ni1102-991. - DOI - PubMed
    1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. doi: 10.1016/j.ccell.2015.03.001. - DOI - PMC - PubMed
    1. Sherr CJ. Principles of tumor suppression. Cell. 2004;116:235–246. doi: 10.1016/S0092-8674(03)01075-4. - DOI - PubMed
    1. Burr ML, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–105. doi: 10.1038/nature23643. - DOI - PMC - PubMed

LinkOut - more resources